Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index; 77 of the 205 sources its claims cite were checked for support.

Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis

Open access

Abstract

Inflammation is a hallmark and potent driver of pathological vascular remodelling in atherosclerosis. However, current anti-inflammatory therapeutic strategies have shown mixed results. As an alternative perspective on the conundrum of chronic inflammation emerging evidence points towards a small subset of senescent cells as a critical player and central node driving atherosclerosis. Senescent cells belonging to various cell types are a dominant and chronic source of a large array of pro-inflammatory cytokines and various additional plaque destabilizing factors, being involved with various aspects of atherosclerosis pathogenesis. Antagonizing these key agitators of local chronic inflammation and plaque instability may provide a causative and multi-purpose therapeutic strategy to treat atherosclerosis. Anti-senescence treatment options with translational potential are currently in development. However, several questions and challenges remain to be addressed before these novel treatment approaches may enter the clinical setting.

Overview

CoChat Summary

TL;DR

This review argues that senescent cells and their senescence-associated secretory phenotype (SASP) are upstream, chronic drivers of inflammation and plaque destabilization in atherosclerosis. It synthesizes experimental and clinical evidence and discusses anti-senescence therapeutic strategies, while highlighting unresolved challenges before clinical translation.

Key findings

  • Senescent endothelial cells, vascular smooth muscle cells (VSMCs), macrophages/foam cells, monocytes, fibroblasts, and T cells accumulate in atherosclerotic arteries and secrete SASP factors including IL-1α, IL-1β, IL-6, IL-8, IL-18, TNF-α, and multiple MMPs, promoting plaque inflammation, cap thinning, calcification, erosion, and intra-plaque angiogenesis.
  • Clinical evidence links senescence to atherosclerosis: 57.1% of men and 68.7% of women older than 70 have atherosclerotic lesions, rising to 87.4% of men and 88.9% of women older than 85; only 11.9% and 40.3% of the age effect in men and women, respectively, is attributable to longer exposure to classical risk factors. In Hutchinson–Gilford progeria, myocardial infarction or stroke occurs at a mean age of 13 years without classical risk factors, and senescent VSMCs accounted for 18% of all plaque cells in human carotid atherosclerosis.
  • Anti-senescence strategies with translational potential include senolytics (e.g., navitoclax, dasatinib plus quercetin), SASP inhibition (e.g., NLRP3, cGAS-STING, JAK, TRAF6, p38 MAPK), energy-sensing pathway modulation (mTOR, SIRT-1, FOXO3, AMPK), epigenetic modulation, and cellular reprogramming; several existing cardiovascular drugs also have anti-senescent effects.
  • The paper identifies key challenges: lack of specific senescence markers, paradoxical pro-atherosclerotic effects of some cell cycle inhibitor knockouts, potential interference with beneficial acute senescence roles, senolytic adverse effects, and the need for better biomarkers and imaging to select patients and track therapy.

Methods

  • Narrative review; no primary data collection or systematic quantitative synthesis.
  • Synthesizes experimental and clinical literature on cellular senescence, SASP, atherosclerosis pathogenesis, and anti-senescence therapies, including preclinical models (e.g., INK-ATTACK, p16-3MR, LDL receptor-knockout mice) and clinical trials/studies (e.g., CANTOS, CIRT, MILES, TAME, idiopathic pulmonary fibrosis senolytic trial).
  • Main analysis is conceptual and mechanistic, organized around cell-specific senescence effects, clinical evidence, therapeutic targets, and future directions.

Limitations

  • The paper states that senescent cell detection is hampered by lack of specific markers; senescence-associated β-galactosidase staining and p16 INK4a expression can yield false-positive results in macrophages, and better understanding of senescence in vascular disease development is needed.
  • It notes that patient selection for anti-senescence trials is challenging because senescence also limits myocardial and liver fibrosis, promotes skin healing, and contributes to embryonal development; oncogenesis risk and the need for senescence-specific biomarkers/imaging remain unresolved.
  • Evident from the text: as a narrative review, it does not provide a systematic search strategy, quantitative synthesis, or new primary data, and many proposed mechanisms and therapies remain preclinical or speculative.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehz919

Cites

210 of 210 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
CC BY-NC · PubMed Central
Figure 1 Cell cycle arrest mechanisms in senescence. CDK, cyclin-dependent kinase; hypo-p-Rb, hypo-phosphorylated retinoblastoma protein. G1, S, G2, and M are cell cycle phases; p16, p53, and p21 are cell cycle inhibitors.
Figure 1 Cell cycle arrest mechanisms in senescence. CDK, cyclin-dependent kinase; hypo-p-Rb, hypo-phosphorylated retinoblastoma protein. G1, S, G2, and M are cell cycle phases; p16, p53, and p21 are cell cycle inhibitors.CC BY-NC · PubMed Central
Figure 2 Roles of different senescent cell types in atherosclerosis, represented in blue. CRP, C-reactive protein; CVD, cardiovascular disease; EC, endothelial cell; ET-1, endothelin-1; ICAM, intercellular adhesion molecule; IL, interleukin; MAPK, mitogen-activated protein kinase; MMP, matrix metalloproteinase; NO, nitric oxide; NF-κB, nuclear factor κB; TNF-α, tumour necrosis factor α; VCAM, vascular cell adhesion molecule; VSMC, vascular smooth muscle cell.
Figure 2 Roles of different senescent cell types in atherosclerosis, represented in blue. CRP, C-reactive protein; CVD, cardiovascular disease; EC, endothelial cell; ET-1, endothelin-1; ICAM, intercellular adhesion molecule; IL, interleukin; MAPK, mitogen-activated protein kinase; MMP, matrix metalloproteinase; NO, nitric oxide; NF-κB, nuclear factor κB; TNF-α, tumour necrosis factor α; VCAM, vascular cell adhesion molecule; VSMC, vascular smooth muscle cell.CC BY-NC · PubMed Central
Figure 3 Putative model of the role of cellular senescence in inflammation-associated cardiovascular disease risk.
Figure 3 Putative model of the role of cellular senescence in inflammation-associated cardiovascular disease risk.CC BY-NC · PubMed Central
Figure 4 Anti-senescence strategies. Akt, protein kinase B; AMPK, AMP-activated protein kinase; cGAS, cyclic GMP-AMP synthase; DPP4, dipeptidyl peptidase 4; FOXO, Forkhead box class O; HMGB-1, high-mobility group box 1; IL, interleukin; MAPK, mitogen-activated protein kinase; mTOR, mechanistic target of rapamycin; NF-κB, nuclear factor kappa B; NLRP3, nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3; ox-vimentin, oxidized vimentin; PI3K, phosphoinositide 3-kinase; SASP, senescence-associated secretory phenotype; SIRT, sirtuin; STING, stimulator of interferon genes; TBK, serine/threonine-protein kinase TBK1; TNFα, tumour necrosis factor α.
Figure 4 Anti-senescence strategies. Akt, protein kinase B; AMPK, AMP-activated protein kinase; cGAS, cyclic GMP-AMP synthase; DPP4, dipeptidyl peptidase 4; FOXO, Forkhead box class O; HMGB-1, high-mobility group box 1; IL, interleukin; MAPK, mitogen-activated protein kinase; mTOR, mechanistic target of rapamycin; NF-κB, nuclear factor kappa B; NLRP3, nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3; ox-vimentin, oxidized vimentin; PI3K, phosphoinositide 3-kinase; SASP, senescence-associated secretory phenotype; SIRT, sirtuin; STING, stimulator of interferon genes; TBK, serine/threonine-protein kinase TBK1; TNFα, tumour necrosis factor α.CC BY-NC · PubMed Central

Verification

Claims the paper makes

30 Valid · 4 Not valid · 73 Not checked · 22 Own results and interpretations

62 more claims · 12 with their cited sources checked

Create a free account to see all 129 claims and to verify the 128 references still open.

See all claims — free account
  • It may state two separate claims as one. 55
  • Probably not a substantial claim. 8

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 209 references

Research works printed but not linked: 2

  1. Prattichizzo, 2016, Aging (Albany NY), 3159
  2. Lakatta, 2015, J Mol Cell Cardiol, 1

Cited by

See all 188

Metadata

Authors
Stojanović, S. D., Fiedler, J., Bauersachs, J., Thum, T., & Sedding, D. G.
Affiliations
  • Medizinische Hochschule Hannover (DE)
  • Martin Luther University Halle-Wittenberg (DE)
Corresponding author
  • Thum, Thomas
  • Sedding, Daniel G
Venue
European Heart Journal
Published
2020-01-03
Volume
41
Issue
31
Pages
2983-2996
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2998051599
Cited by
188
References
209
Citations by year
2026: 23 · 2025: 31 · 2024: 26 · 2023: 27 · 2022: 33 · 2021: 35 · 2020: 12
FWCI
7.98
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Deutsche Forschungsgemeinschaft (KFO FOR311-2, TH903/20-1)
  • Cluster of Excellence REBIRTH
  • Regenerative Biology to Reconstructive Therapy EXC 62
  • German Academic Exchange Service Graduate School Scholarship Programme (57320205)
  • Foundation Leducq
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
Keywords
senescence-associated inflammation, cellular senescence, atherosclerosis, chronic inflammation, inflammatory cytokines, plaque vulnerability, vascular remodeling, anti-senescence therapy, atherosclerotic plaque
MeSH terms
Humans, Inflammation, Cytokines, Cellular Senescence, Atherosclerosis, Plaque, Atherosclerotic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis. https://app.cochat.ai/papers/10.1093/eurheartj/ehz919
The paper
Stojanović, S. D., Fiedler, J., Bauersachs, J., Thum, T., & Sedding, D. G. (2020). Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis. European Heart Journal. https://doi.org/10.1093/eurheartj/ehz919

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.